300519 新光药业
已收盘 11-12 15:00:00
资讯
新帖
简况
新光药业：常规研发不属于强制审查范围
证券之星 · 09:06
新光药业：常规研发不属于强制审查范围
新光药业（300519）11月9日主力资金净卖出631.40万元
证券之星 · 11-09 15:44
新光药业（300519）11月9日主力资金净卖出631.40万元
新光药业：公司对资本市场中的并购重组始终持积极开放的态度
证券之星 · 11-03
新光药业：公司对资本市场中的并购重组始终持积极开放的态度
新光药业（300519）10月26日主力资金净买入1140.73万元
证券之星 · 10-26
新光药业（300519）10月26日主力资金净买入1140.73万元
股市必读：新光药业三季报 - 第三季度单季净利润同比增长81.61%
证券之星 · 10-26
股市必读：新光药业三季报 - 第三季度单季净利润同比增长81.61%
新光药业（300519）2026年三季报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 10-24
新光药业（300519）2026年三季报简析：营收净利润同比双双增长，三费占比上升明显
新光药业（300519）10月23日主力资金净买入530.60万元
证券之星 · 10-23
新光药业（300519）10月23日主力资金净买入530.60万元
股市必读：新光药业新发布《2026年三季度报告》
证券之星 · 10-23
股市必读：新光药业新发布《2026年三季度报告》
新光药业：第五届董事会第十次会议决议公告
证券日报网 · 10-22
新光药业：第五届董事会第十次会议决议公告
新光药业(300519)9月30日股东户数1.43万户，较上期增加4.78%
证券之星 · 10-22
新光药业(300519)9月30日股东户数1.43万户，较上期增加4.78%
新光药业（300519）9月28日主力资金净买入93.47万元
证券之星 · 09-28
新光药业（300519）9月28日主力资金净买入93.47万元
新光药业：省外市场拓展正在稳步推进中
证券之星 · 09-23
新光药业：省外市场拓展正在稳步推进中
9月21日新光药业涨5.46%，工银聚享混合A基金重仓该股
证券之星 · 09-21
9月21日新光药业涨5.46%，工银聚享混合A基金重仓该股
9月3日新光药业发布公告，股东减持79.7万股
证券之星 · 09-03
9月3日新光药业发布公告，股东减持79.7万股
新光药业（300519）2026年中报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 08-26
新光药业（300519）2026年中报简析：营收净利润同比双双增长，三费占比上升明显
新光药业(300519)6月30日股东户数1.36万户，较上期减少8.76%
证券之星 · 08-25
新光药业(300519)6月30日股东户数1.36万户，较上期减少8.76%
新光药业（300519）披露2026年1-6月非经营性资金占用及其他关联资金往来情况表，8月24日股价下跌1.47%
证券之星 · 08-24
新光药业（300519）披露2026年1-6月非经营性资金占用及其他关联资金往来情况表，8月24日股价下跌1.47%
图解新光药业中报：第二季度单季净利润同比增长81.16%
证券之星 · 08-24
图解新光药业中报：第二季度单季净利润同比增长81.16%
股市必读：新光药业（300519）7月28日董秘有最新回复
证券之星 · 07-29
股市必读：新光药业（300519）7月28日董秘有最新回复
7月28日新光药业涨5.34%，工银聚享混合A基金重仓该股
证券之星 · 07-28
7月28日新光药业涨5.34%，工银聚享混合A基金重仓该股
加载更多
公司概况
公司名称：
浙江新光药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-06-24
主营业务：
浙江新光药业股份有限公司的主营业务是中成药、化学药、保健食品的研发、生产和销售。公司的主要产品是黄芪生脉饮、伸筋丹胶囊、西洋参口服液。
发行价格：
12.20
{"stockData":{"symbol":"300519","market":"SZ","secType":"STK","nameCN":"新光药业","latestPrice":14.96,"timestamp":1794467028000,"preClose":14.6,"halted":0,"volume":6043100,"delay":0,"changeRate":0.0247,"floatShares":113999999,"shares":160000000,"eps":0.4561,"marketStatus":"已收盘","change":0.36,"latestTime":"11-12 15:00:00","open":14.58,"high":15.29,"low":14.53,"amount":90351300,"amplitude":0.0521,"askPrice":14.96,"askSize":71,"bidPrice":14.95,"bidSize":355,"shortable":0,"etf":0,"ttmEps":0.4561,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794533400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.6,"symbolType":"stock","openAndCloseTimeList":[[1794447000000,1794454200000],[1794459600000,1794466800000]],"highLimit":16.06,"lowLimit":13.14,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":160000000,"isCdr":false,"pbRate":2.74,"roa":"--","peRate":32.799825,"roe":"7.56%","epsLYR":0.34,"committee":0.026877,"marketValue":2394000000,"turnoverRate":0.053,"status":0,"floatMarketCap":1707000000},"requestUrl":"/m/hq/s/300519/","defaultTab":"news","newsList":[{"id":"2682395545","title":"新光药业：常规研发不属于强制审查范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2682395545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682395545?lang=zh_cn&edition=full","pubTime":"2026-11-12 09:06","pubTimestamp":1794445573,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业11月11日在投资者关系平台上答复投资者关心的问题。关注到公司主营植物类中药制剂。请问公司研发活动是否属于《科技伦理审查办法（试行）》规定的审查范围？新光药业为中成药制药企业，主要从事中成药、保健食品的研发、生产和销售。后续如公司研发布局发生重大变化、出现需要自建伦理审查机制的情形，公司将依规完善相关治理安排。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200007263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682703678","title":"新光药业（300519）11月9日主力资金净卖出631.40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682703678","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682703678?lang=zh_cn&edition=full","pubTime":"2026-11-09 15:44","pubTimestamp":1794210285,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月9日收盘，新光药业报收于14.16元，下跌2.68%，换手率3.02%，成交量3.44万手，成交额4943.22万元。11月9日的资金流向数据方面，主力资金净流出631.4万元，占总成交额12.77%，游资资金净流入111.31万元，占总成交额2.25%，散户资金净流入520.09万元，占总成交额10.52%。新光药业主营业务：主要从事中成药、化学药、保健食品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110900009766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680292867","title":"新光药业：公司对资本市场中的并购重组始终持积极开放的态度","url":"https://stock-news.laohu8.com/highlight/detail?id=2680292867","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680292867?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:52","pubTimestamp":1793710360,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问，贵公司资产负债率很低，账上现金7.5亿，并且现金流挺好，大股东和二股东合计持股50%，请问贵公司，对于并购重组持什么样的态度？难道不想着，做大做强再创辉煌吗？新光药业回复：您好，感谢您对本公司的关注。公司对资本市场中的并购重组始终持积极开放的态度。在当前经济形势下，公司董事会始终立足经营实际，审慎制定发展战略，根据行业环境、市场需求变化及时调整经营策略，以切实维护股东利益。谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300041058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519","161123"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678579941","title":"新光药业（300519）10月26日主力资金净买入1140.73万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678579941","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678579941?lang=zh_cn&edition=full","pubTime":"2026-10-26 15:31","pubTimestamp":1792999898,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月26日收盘，新光药业报收于15.49元，上涨3.06%，换手率12.11%，成交量13.82万手，成交额2.09亿元。10月26日的资金流向数据方面，主力资金净流入1140.73万元，占总成交额5.45%，游资资金净流入1585.73万元，占总成交额7.57%，散户资金净流出2726.46万元，占总成交额13.02%。新光药业主营业务：主要从事中成药、化学药、保健食品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600015008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678813962","title":"股市必读：新光药业三季报 - 第三季度单季净利润同比增长81.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678813962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678813962?lang=zh_cn&edition=full","pubTime":"2026-10-26 04:32","pubTimestamp":1792960329,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告新光药业2026年三季报显示，前三季度主营收入2.11亿元，同比上升2.6%；归母净利润6410.02万元，同比上升41.39%；扣非净利润6064.88万元，同比上升39.46%。公司公告汇总2026年三季度报告浙江新光药业股份有限公司2026年第三季度报告显示，本报告期营业收入为68,364,946.91元，同比增长5.70%；归属于上市公司股东的净利润为24,388,088.60元，同比增长81.61%。年初至报告期末营业收入为210,958,037.00元，同比增长2.60%；归属于上市公司股东的净利润为64,100,161.06元，同比增长41.39%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600001141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677397077","title":"新光药业（300519）2026年三季报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2677397077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677397077?lang=zh_cn&edition=full","pubTime":"2026-10-24 06:09","pubTimestamp":1792793376,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新光药业发布2026年三季报。截至本报告期末，公司营业总收入2.11亿元，同比上升2.6%，归母净利润6410.02万元，同比上升41.39%。按单季度数据看，第三季度营业总收入6836.49万元，同比上升5.7%，第三季度归母净利润2438.81万元，同比上升81.61%。本报告期新光药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达36.27%。本文数据来源于新光药业2026年三季报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400005355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677412946","title":"新光药业（300519）10月23日主力资金净买入530.60万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677412946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677412946?lang=zh_cn&edition=full","pubTime":"2026-10-23 15:28","pubTimestamp":1792740504,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，新光药业报收于15.03元，上涨8.83%，换手率11.86%，成交量13.53万手，成交额2.01亿元。10月23日的资金流向数据方面，主力资金净流入530.6万元，占总成交额2.63%，游资资金净流入886.05万元，占总成交额4.4%，散户资金净流出1416.65万元，占总成交额7.03%。新光药业主营业务：主要从事中成药、化学药、保健食品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300023095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677257994","title":"股市必读：新光药业新发布《2026年三季度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677257994","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677257994?lang=zh_cn&edition=full","pubTime":"2026-10-23 05:11","pubTimestamp":1792703472,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘，新光药业报收于13.81元，下跌3.7%，换手率2.36%，成交量2.7万手，成交额3771.3万元。股本股东变化：截至2026年9月30日股东户数为1.43万户，较6月30日增加4.78%，户均持股由1.17万股降至1.12万股。公司公告汇总2026年三季度报告2026年第三季度营业收入为68,364,946.91元，同比增长5.70%；归属于上市公司股东的净利润为24,388,088.60元，同比增长81.61%。年初至报告期末营业收入为210,958,037.00元，同比增长2.60%；归属于上市公司股东的净利润为64,100,161.06元，同比增长41.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300004649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677802965","title":"新光药业：第五届董事会第十次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2677802965","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677802965?lang=zh_cn&edition=full","pubTime":"2026-10-22 19:53","pubTimestamp":1792669980,"startTime":"0","endTime":"0","summary":"证券日报网讯 10月22日，新光药业发布公告称，公司于2026年10月21日召开第五届董事会第十次会议，审议通过《关于〈公司2026年第三季度报告〉的议案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-10-22/doc-iniwcaff5223894.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-10-22/doc-iniwcaff5223894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300519","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677956946","title":"新光药业(300519)9月30日股东户数1.43万户，较上期增加4.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677956946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677956946?lang=zh_cn&edition=full","pubTime":"2026-10-22 17:53","pubTimestamp":1792662828,"startTime":"0","endTime":"0","summary":"证券之星消息，近日新光药业披露，截至2026年9月30日公司股东户数为1.43万户，较6月30日增加651.0户，增幅为4.78%。在中药行业个股中，新光药业股东户数低于行业平均水平，截至9月30日，中药行业平均股东户数为5.23万户。从股价来看，2026年6月30日至2026年9月30日，新光药业区间涨幅为25.06%，在此期间股东户数增加651.0户，增幅为4.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200030865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670282871","title":"新光药业（300519）9月28日主力资金净买入93.47万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670282871","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670282871?lang=zh_cn&edition=full","pubTime":"2026-09-28 15:32","pubTimestamp":1790580755,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，新光药业报收于14.65元，上涨0.62%，换手率1.93%，成交量2.2万手，成交额3210.36万元。9月28日的资金流向数据方面，主力资金净流入93.47万元，占总成交额2.91%，游资资金净流入211.84万元，占总成交额6.6%，散户资金净流出305.31万元，占总成交额9.51%。新光药业主营业务：主要从事中成药、化学药、保健食品的研发、生产和销售。当天两者的差额即是当天两种力量相抵之后剩下的推动股价上升的净力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800014753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669669486","title":"新光药业：省外市场拓展正在稳步推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2669669486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669669486?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:51","pubTimestamp":1790167919,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业09月22日在投资者关系平台上答复投资者关心的问题。公司董事会始终立足经营实际，审慎制定发展战略，根据行业环境、市场需求变化及时调整IPO 募投项目的投向，并按规定履行信息披露义务。公司持续深耕现有市场，省外市场拓展正在稳步推进中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300038446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159213","title":"9月21日新光药业涨5.46%，工银聚享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159213?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:46","pubTimestamp":1789980391,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日新光药业涨5.46%，收盘报14.68元，换手率3.44%，成交量3.93万手，成交额5683.17万元。重仓新光药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为工银瑞信基金的工银聚享混合A。工银聚享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100021020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300519","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664987172","title":"9月3日新光药业发布公告，股东减持79.7万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664987172","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664987172?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:01","pubTimestamp":1788436882,"startTime":"0","endTime":"0","summary":"证券之星消息，9月3日新光药业发布公告《新光药业:关于公司持股5%以上股东股份减持计划届满的公告》，其股东嵊州市和丰投资股份有限公司于2026年8月25日至2026年9月2日间合计减持79.7万股，占公司目前总股本的0.4981%，变动期间该股股价上涨3.41%，截止9月2日收盘报14.56元。股东增减持详情见下表：根据新光药业2026年中报公布的十大股东详情如下：本文数据来源于新光药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300038193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750493","title":"新光药业（300519）2026年中报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750493?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:30","pubTimestamp":1787697021,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新光药业发布2026年中报。截至本报告期末，公司营业总收入1.43亿元，同比上升1.17%，归母净利润3971.21万元，同比上升24.46%。本报告期新光药业三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达61.19%。营业利润变动幅度为25.86%,原因:营业成本减少、毛利率增加。本文数据来源于新光药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600010287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738254","title":"新光药业(300519)6月30日股东户数1.36万户，较上期减少8.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738254","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662738254?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:53","pubTimestamp":1787651606,"startTime":"0","endTime":"0","summary":"证券之星消息，近日新光药业披露，截至2026年6月30日公司股东户数为1.36万户，较3月31日减少1308.0户，减幅为8.76%。在中药行业个股中，新光药业股东户数低于行业平均水平，截至6月30日，中药行业平均股东户数为5.3万户。从股价来看，2026年3月31日至2026年6月30日，新光药业区间跌幅为21.34%，在此期间股东户数减少1308.0户，减幅为8.76%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500037704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729522","title":"新光药业（300519）披露2026年1-6月非经营性资金占用及其他关联资金往来情况表，8月24日股价下跌1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661729522?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:31","pubTimestamp":1787581887,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，新光药业报收于14.08元，较前一交易日下跌1.47%，最新总市值为22.53亿元。该股当日开盘14.17元，最高14.44元，最低13.94元，成交额达5571.5万元，换手率为3.46%。公告显示，公司编制了2026年1-6月非经营性资金占用及其他关联资金往来情况汇总表，表格包括控股股东、实际控制人及其附属企业、上市公司的子公司及其附属企业、其他关联方及其附属企业的资金往来情况。该报表由法定代表人、主管会计工作负责人及会计机构负责人签章。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400037590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661122026","title":"图解新光药业中报：第二季度单季净利润同比增长81.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661122026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661122026?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:15","pubTimestamp":1787566547,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业2026年中报显示，上半年度公司主营收入1.43亿元，同比上升1.17%；归母净利润3971.21万元，同比上升24.46%；扣非净利润3620.94万元，同比上升23.0%；其中2026年第二季度，公司单季度主营收入5412.38万元，同比上升13.48%；单季度归母净利润1334.41万元，同比上升81.16%；单季度扣非净利润1097.09万元，同比上升80.66%；负债率6.05%，投资收益353.95万元，财务费用-124.42万元，毛利率46.06%。财报数据概要请见下图:本文数据来源于新光药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400026104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655088113","title":"股市必读：新光药业（300519）7月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2655088113","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655088113?lang=zh_cn&edition=full","pubTime":"2026-07-29 01:38","pubTimestamp":1785260293,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，新光药业报收于13.8元，上涨5.34%，换手率9.19%，成交量10.49万手，成交额1.45亿元。董秘最新回复投资者： 请问截止目前，贵公司的股东户数是多少董秘： 您好，感谢您对本公司的关注。为保证信息披露的公平性，公司会在定期报告中对股东情况作出统一披露。交易信息汇总资金流向7月28日主力资金净流入400.09万元；游资资金净流入988.49万元；散户资金净流出1388.58万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900001164.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654444077","title":"7月28日新光药业涨5.34%，工银聚享混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2654444077","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654444077?lang=zh_cn&edition=full","pubTime":"2026-07-28 16:56","pubTimestamp":1785228967,"startTime":"0","endTime":"0","summary":"证券之星消息，7月28日新光药业涨5.34%，收盘报13.8元，换手率9.19%，成交量10.49万手，成交额1.45亿元。重仓新光药业的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为工银瑞信基金的工银聚享混合A。工银聚享混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800027041.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794468655935,"stockEarnings":[{"period":"1week","weight":0.0146},{"period":"1month","weight":-0.0054},{"period":"3month","weight":0.0041},{"period":"6month","weight":-0.0561},{"period":"1year","weight":-0.1043},{"period":"ytd","weight":0.001}],"compareEarnings":[{"period":"1week","weight":-0.0015},{"period":"1month","weight":-0.0307},{"period":"3month","weight":-0.0627},{"period":"6month","weight":-0.11},{"period":"1year","weight":-0.0805},{"period":"ytd","weight":-0.0726}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江新光药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"14273人(较上一季度增加4.78%)","perCapita":"7994股","listingDate":"2016-06-24","address":"浙江省绍兴市嵊州市剡湖街道环城西路25号","registeredCapital":"16000万元","survey":" 浙江新光药业股份有限公司的主营业务是中成药、化学药、保健食品的研发、生产和销售。公司的主要产品是黄芪生脉饮、伸筋丹胶囊、西洋参口服液。","listedPrice":12.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新光药业,300519,新光药业股票,新光药业股票老虎,新光药业股票老虎国际,新光药业行情,新光药业股票行情,新光药业股价,新光药业股市,新光药业股票价格,新光药业股票交易,新光药业股票购买,新光药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}